User:Enrospv/Nanatinostat

Nanatinostat is an orally bioavailable HDAC inhibitor developed by Viracta Therapeutics for the treatement of Epstein–Barr virus-associated lymphoproliferative diseases in combination with valganciclovir.

Side effects include cytopenias such as thrombocytopenia, neutropenia and lymphopenia and long QT syndrome at high doses.